Harvard Bioscience acquires CMA Microdialysis' preclinical business
Harvard Bioscience Inc., a global developer of tools for life science research and regenerative medicine, announced last month that it has acquired the preclinical business unit of CMA Microdialysis AB through a purchase of assets.
HOLLISTON, Mass.—Harvard Bioscience Inc., a global developerof tools for life science research and regenerative medicine, announced lastmonth that it has acquired the preclinical business unit of CMA MicrodialysisAB through a purchase of assets.
CMA Microdialysis AB is a privately held Swedishmanufacturer of microdialysis products. Founded in 1984, the company pioneeredthe microdialysis technique for in-vivosampling and monitoring of organs and tissues.
Harvard Bioscience says the acquisition is complementary toits Harvard Apparatus research products for neuroscience applications.
"The acquisition of CMA Microdialysis' preclinical businessprovides Harvard with a leading technology to add to our line of specializedtools for biological research," added Harvard Bioscience CEO Chane Graziano ina press release announcing the deal.
The business unit will remain in Sweden. Renamed DipylonMedical AB, the unit will have two business divisions: Eirus Medical, whichwill focus on the development of novel continuous blood glucose and lactatemonitoring systems based on smart catheter solutions, and ClinicalMicrodialysis, which will focus on the development, production and marketing oftissue monitoring solutions for in-vivomonitoring of injured organs.
Financial terms of the acquisition were not released.Harvard Bioscience says it expects the acquisition to be immediately accretiveto earnings.
Philip Siberg, CEO of CMA Microdialysis, stated that theacquisition has long-term strategic value for the company, as it creates valuefor its employees and customers.
